Clinical Pathways

Clinical Pathways Help Integrate New Drugs, Reduce Variability in Care Delivery

Charles Bankhead

October 2017, Vol 7, No 10 - Clinical Pathways

Chicago, IL—Clinical pathways have an important role in the integration of new cancer drugs into clinical practice. Between January 2015 and mid-2017, the FDA granted more than 60 new approvals in oncology, with new drugs accounting for the vast majority (as opposed to new indications). Staying abreast of new drugs and new indications for specific types of cancer requires much time, which presents an extra burden on community oncologists. [ Read More ]

Clinical Pathways: Agents of Change Toward Patient-Centric Care

Chase Doyle

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017 - Clinical Pathways

Chicago, IL—Developed in the early 2000s, clinical pathways are being increasingly used by providers. According to ASCO’s The State of Cancer Care in America, 2016 report, there was a 46% increase in the provider use of clinical pathways between 2014 and 2015, and that figure now exceeds 50%, reported Robin Zon, MD, FACP, FASCO, Medical Oncologist, Michiana Hematology Oncology Advanced Centers for Cancer Care, South Bend, IN, and Chair of the ASCO Task Force on Clinical Pathways, at the 2017 ASCO annual meeting. Dr Zon described the potential role of high-quality clinical pathways in payment reform and utilization management and forecasted the future of clinical pathways, with possible returns on investment. [ Read More ]